OIRA Conclusion of EO 12866 Regulatory Review

RIN: 1545-BR16         View EO 12866 Meetings	Received Date: 11/14/2025
Title: Branded Prescription Drug Fee Discounts
Agency/Subagency: TREAS / IRS	Stage: Proposed Rule
Concluded Action: Consistent with Change	Concluded Date: 12/22/2025
Legal Deadline: None	Economically Significant: No
Publication Date:	Unfunded Mandates: No
Major:	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: No	Small Entities Affected: No
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No